Thank you Princess Margaret Cancer Centre for sharing this information with us:
Dear Canadian MPN Research Foundation and patients/caregivers of patients with MPN,
We are excited to inform you about a series of new generation immunotherapy clinical trials opening at Princess Margaret for MPN patients.
These immunotherapy trials are specifically for CALR mutated patients with Essential Thrombocythemia (ET), Myelofibrosis (MF), and Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) in chronic (blasts <10%) OR accelerated phase (blasts 10-19%) of the disease. At present, the eligibility criteria for these trials require patients to have failed at least one line of therapy. These targeted treatments are at an early phase and experimental in nature. If deemed safe, there is hope that such treatments may achieve better disease control or disease eradication.
Over the last 10 years, the MPN Program at Princess Margaret has invested heavily in the infrastructure of our program to facilitate such trials.
Any patients with CALR mutated MPN should discuss with their hematologist about a referral for consideration for these trials. Referrals from health care providers can be faxed to Princess Margaret New Patient Referrals at 416-946-2900, marked as CALR mutated MPN patient with attention to Dr. Vikas Gupta.